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Abstract
Objectives: New antidiabetic medications such as insulin analogues and thiazolidinediones have been introduced
over the last decade. This study compares the uptake of new agents in three emerging pharmaceutical markets:
Brazil, China, and Thailand.
Methods: Using longitudinal IMS Health sales data, we calculated the quarterly percentage market share for types
of insulins and oral hypoglycemic agents from 2002 through 2012 in each country. New oral hypoglycemic agents
included: alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and non-sulfonylurea
secretagogues.
Results: While China had the highest use of insulin cartridges and pens (85.6% in 2010), Brazil was the earliest
adopter of insulin analogues and had the greatest use of these products overall (44.6% of the insulin market) in
2010, which then decreased by almost half by 2012. Together, sulfonylureas and metformin dominated the markets
in Brazil and Thailand (~89% and ~96% respectively) over the 10-year period. Between 2002 and 2012, there was a
shift in use from sulfonylureas to metformin; the market share of newer agents remained 10% or less in both
countries. In China, however, market share of new oral agents grew rapidly from 13.1% to 44.4%. While metformin
use was relatively stable in China (one-third of the market), sulfonylureas declined substantially over the 10-year
period (41.5% to 20.8%).
Conclusion: Given large cost differentials between newer and older insulins and among oral hypoglycemic agents,
it is important to evaluate uptake of newer products over time. Uptake patterns differed in the study countries,
likely due to different medicines policy approaches. Future research should evaluate how trends in use of
antidiabetic products align with national clinical practice guidelines and pharmaceutical policies, as well as the
impacts of different patterns of use on cost and clinical outcomes.
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Introduction
Increasing health care expenditures are a common con-
cern worldwide. Increases are associated with several fac-
tors, including expanding access to insurance coverage,
aging populations, and new expensive medicines and tech-
nologies. Every country has a structure of health and
pharmaceutical policies that influences patient access to
health services and medicines. Middle-income countries
with large populations, rapidly growing economies, and
large contributions to global pharmaceutical market
growth – often referred to as “pharmerging” markets [1] –
face multiple challenges including growing chronic disease
burden, rising consumer expectations for health care, and
increasing financial stresses in their health and pharma-
ceutical sectors.
Diabetes is one of the most common chronic conditions
in nearly all countries, affecting approximately 382 million
individuals worldwide with another 316 million individuals
with impaired glucose tolerance who are at high risk of
diabetes [2]. About 80% of people with diabetes live in
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low- and middle-income countries. All types of diabetes
are increasing, particularly type 2 diabetes; the number of
people affected by diabetes is estimated to increase by 55%
by 2035. Diabetes is a major cause of morbidity and mor-
tality in many countries. Globally, it caused 5.1 million
deaths in 2013 and accounted for about 11% of total
healthcare expenditures for adults (US$548 billion) [2].
Oral hypoglycemics and insulins are the mainstay of phar-
macotherapies for treating both type 2 and type 1 diabetes
[2]. While these may be regarded as relatively inexpensive
pharmaceutical products by well-funded health systems in
industrialized countries, it is not so in resource-limited
countries. New oral hypoglycemic medications (thiazolidine-
diones and dipeptidyl peptidase inhibitors) and new insulin
molecules and delivery formulations (insulin analogues, hu-
man insulin and insulin analogues administered via pens)
have become available over the last decade; these are more
expensive than older products (e.g., metformin, human insu-
lins in vials and syringes).
This study compares the uptake of new insulin products
and new oral hypoglycemic medications between three
middle-income pharmerging countries: Brazil, China, and
Thailand. The prevalence of diabetes in Brazil, China and
Thailand in 2011 was 9.0%, 9.6% and 6.4%, respectively
[2]. During the study period, all three countries have rap-
idly expanded health and pharmaceutical coverage. Brazil
and Thailand have emphasized access to essential generic
medicines in their universal coverage programs [3-5]; in
China, hospitals’ historical reliance on medicines sales for
revenue has created incentives for use of higher cost prod-
ucts [6,7]. Given their different policy contexts, these
countries are likely to have responded differently to ex-
panded availability and marketing of newer, more expen-
sive insulins and oral hypoglycemics for diabetes.
Methods
Data sources
We used quarterly pharmaceutical purchasing data col-
lected by IMS Health (2002 through 2012). The sales data
are generated from reports to IMS Health by multi-
national pharmaceutical companies and surveys of pur-
chases by hospital and retail pharmacies.
In Thailand, the IMS Health data come from a sample
of approximately 200 of about 1100 general and special-
ized public and private hospitals in the country and 350
retail pharmacies. In Brazil, the IMS Health data represent
sales by more than 58,000 pharmacies, based on data from
130 pharmacies (direct sales) and more than 400 whole-
salers (indirect sales). Dispensings under the Popular
Pharmacy Program [8], a largely private pharmacy net-
work implemented in 2006 to increase access to essential
medicines, are captured by the IMS data. In China, the
IMS Health data come from a systematic sample of about
15% of hospitals with at least 100 beds (810 general and
208 specialized hospitals) across the country. Approxi-
mately 80% of medicines in China are sold in hospitals [9].
IMS Health updated sampling strategies in December
2009 and April 2010 in Brazil and China, respectively, to
expand market coverage.
The IMS database classifies medicines according to the
European Pharmaceutical Market Research Association
(EphMRA) Anatomical Therapeutic Chemical (ATC) classi-
fication system, and contains details about the generic drug
name, product name, pack size, manufacturer, licensing sta-
tus, launch date, and volume purchased (sold) in standard
units. IMS Health defines a standard unit as the smallest
common dose of a product form: one tablet or capsule for
oral formulations, one teaspoon (5 ml) for syrups, and one
ampoule, vial, or cartridge for parenteral formulations. For
insulins, volume purchased was measured in international
units.
Outcome measures and data analysis
We analyzed the use of all antidiabetic medications mar-
keted in the three countries. For each country, we exam-
ined use and types and formulations of insulin and oral
hypoglycemic agents, from 2002 through 2012.
Insulins included animal and human insulin products,
and insulin analogues (genetically engineered insulin
products). We also classified insulin products according
delivery devices: (a) prefilled pens/cartridges, and (b) con-
ventional vials/syringes. Newer delivery devices (pens and
cartridges), although more expensive, may be favored as
they can provide more accurate dosing, less pain due to
smaller needle gauge, increased social acceptability, better
quality of life, and potentially greater adherence [10]. We
excluded Exubera, an inhaled insulin, from the analyses; it
was used only in Brazil between 2007 and 2008, account-
ing for less than 0.5% of market share.
Oral hypoglycemics included biguanides, sulfonylureas,
alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibi-
tors (DPP4 inhibitors), non-sulfonylurea secretagogues,
thiazolidinediones, and fixed dose combinations of those
molecules. We defined the latter four types as “newer” oral
hypoglycemic products since they were more recently
brought to market than biguanides and sulfonylureas,
which remain the mainstay of oral therapy for diabetes in
most clinical guidelines.
We used market share for each product based on mar-
ket volume as our main outcome measure; we used a simi-
lar measure in our previous study [11]. For our analysis, a
product was defined as the unique combination of ingredi-
ent, dosage form, and strength. Market volume was de-
fined as the number of standard units for oral dosage
forms (and international units for insulin) purchased
(sold) per 1000 population per quarter. Yearly estimates of
the population for each country were obtained from the
World Bank to control for population changes over time
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[12]. Because insulin products could be used by patients of
any age, we used total population estimates for analyses of
the insulin market, and adult (15 years and older) popula-
tion estimates for the oral hypoglycemic market. To under-
stand how much a product was used in relation to
therapeutic alternatives on the market, we also calculated
percentage market share. For example, market share of insu-
lin analogues was defined as the analogue insulin percentage
of the total market volume (in international units) for all in-
sulin products in the country.
The study was determined to be exempt from human sub-
jects review by the institutional review board of the Harvard
Pilgrim Health Care Institute (Boston, Massachusetts).
Results
Insulin products
Overall use of insulin analogues (regardless of delivery
devices), as measured by market share, increased over
time in Brazil, China, and Thai retail settings (Table 1)
(Figure 1); the increase was very small in Thai hospitals.
Table 1 Market shares* of insulin pens/cartridges and vials/syringes by country (2002 to 2012)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
BRAZIL ***
Pens/cartridges** 26.17 29.46 34.71 32.75 36.05 38.15 40.37 43.59 46.38 36.71 29.91
Analogue 1.82 3.89 8.56 14.43 21.38 26.53 30.11 33.43 36.47 27.73 19.81
Human 24.34 25.57 26.15 18.31 14.67 11.62 10.26 10.16 9.91 8.98 10.10
Vials/syringes** 73.83 70.54 65.29 67.25 63.95 61.85 59.63 56.41 53.62 63.29 70.09
Analogue 2.11 2.78 4.14 5.68 6.55 7.17 7.20 7.60 8.12 5.32 4.22
Animal 24.16 19.73 15.40 14.39 5.88 0.55 0.00 0.00 0.00 0.00 0.00
Human 47.56 48.03 45.75 47.19 51.52 54.12 52.43 48.81 45.50 57.97 65.87
CHINA
Pens/cartridges** 43.61 48.41 55.81 62.33 67.69 72.71 77.21 80.14 82.86 84.69 85.66
Analogue 0.00 0.33 0.58 1.31 3.58 8.02 14.20 20.35 25.52 30.23 33.92
Animal 0.00 0.00 0.00 0.00 0.31 0.53 0.67 0.62 0.77 0.92 0.52
Human 43.61 48.07 55.23 61.03 63.80 64.16 62.34 59.17 56.57 53.54 51.21
Vials/syringes ** 56.39 51.59 44.19 37.67 32.31 27.29 22.79 19.86 17.14 15.31 14.34
Analogue 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.03
Animal 39.18 36.64 30.33 24.25 21.61 18.08 15.35 14.34 12.72 11.47 10.46
Human 17.21 14.96 13.86 13.42 10.70 9.19 7.44 5.51 4.42 3.84 3.85
THAILAND HOSPITAL
Pens/cartridges** 9.25 11.36 15.92 23.46 31.08 37.30 40.83 47.48 48.26 48.95 51.02
Analogue 0.15 0.23 0.41 1.15 1.98 3.66 4.78 5.84 6.24 6.12 6.66
Human 9.10 11.13 15.52 22.31 29.10 33.63 36.05 41.65 42.02 42.83 44.36
Vials/syringes** 90.75 88.64 84.08 76.54 68.92 62.70 59.17 52.52 51.74 51.05 48.98
Analogue 0.00 0.24 0.81 0.79 0.51 0.44 0.36 0.25 0.23 0.17 0.12
Human 90.75 88.40 83.27 75.75 68.42 62.27 58.81 52.27 51.51 50.88 48.86
THAILAND RETAIL
Pens/cartridges ** 15.91 17.12 21.40 25.78 30.18 38.99 44.37 45.44 54.21 59.35 62.02
Analogue 0.23 0.50 0.62 1.32 2.75 6.86 10.36 15.01 21.33 24.21 27.43
Human 15.68 16.61 20.78 24.46 27.43 32.13 34.01 30.43 32.88 35.14 34.59
Vials/syringes** 84.09 82.88 78.60 74.22 69.82 61.01 55.63 54.56 45.79 40.65 37.98
Analogue 0.00 0.00 0.00 0.00 0.10 0.86 1.23 1.26 1.22 0.72 0.72
Human 84.09 82.88 78.60 74.22 69.72 60.15 54.40 53.29 44.57 39.93 37.26
*Market share is the percentage of the total market volume based on volume sold in international units per 1000 population.
**Pens/cartridges includes: CARTRIDGES, P-F PENS, CARTRIDGES RET and P-F PENS RET. Vials/syringes includes: VIAL, VIAL SC and VIAL SC RET.
***Exubera was excluded from the analysis because it is an inhaled insulin thus it does not fit the classification applied; it was used only in Brazil, in the years
2007 and 2008, accounting for only 0.15 and 0.03% of the market share.
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The increase was steepest in Brazil, although this up-
ward trend reversed sharply starting in early 2011.
Brazil was the earliest and most rapid adopter of insulin
analogues. By 2010, Brazil also had a much higher use of
insulin analogues overall, accounting for 44.6% of the in-
sulin market, which was substantially greater than use in
China (25.5%) and Thailand (6.5% in hospitals; 22.5% in
retail pharmacies) at that time. In 2011 and 2012, however,
analogue use in Brazil decreased sharply. China was the
only country that maintained use of animal insulin prod-
ucts throughout the entire study period, although the rate
declined steadily (39.2% in 2002 to 11.0% in 2012). We did
not observe any use of animal insulin products in
Thailand during the 10-year period, and its use ceased
after 2007 in Brazil. Human insulin products dominated
the Thailand hospital and retail markets during the study
period (Figure 1).
Similarly, pen/cartridge use generally increased over
time in all settings. In Brazil, pen/cartridge use increased
to 46.4% market share in 2010 (about three-quarters of
these were insulin analogues), but decreased markedly
from 2011 onwards. China had the highest use of insulin
pens and cartridges (Table 1), accounting for 43.6% of the
insulin market in 2002 and 85.7% in 2012; about two-
thirds of these were human insulin pens/cartridges. In
contrast, Thailand had the lowest use of insulin pens and
cartridges in 2002 (9.3% in hospitals; 15.9% in retail set-
tings); although lower than Brazil’s in 2002, Thailand’s use
of insulin pens/cartridges (in both hospital and retail set-
tings) overtook Brazil’s in 2008, reaching 51.0% and 62.0%
in 2012 in Thai hospital and retail settings, respectively.
Oral hypoglycemic products
In all settings, biguanide use increased and sulfonylurea
use decreased over the study period. However, in China
there was a clear shift in use from biguanides and sulfo-
nylureas to newer oral antidiabetic medicines.
China had the highest use of newer oral hypoglycemic
products (Figure 2); market share of these agents grew rap-
idly from 13.1% in 2002 to 44.4% in 2012. Use of alpha-
glucosidase inhibitors accounted for the majority of this
higher use (Table 2), followed by non-sulfonylurea secreta-
gogues. While metformin use was relatively stable in China
(about one-third of the market), sulfonylureas declined sub-
stantially over the 10-year period (41.5% to 20.8%).
Use of newer oral hypoglycemic products in Brazil was
stable from 2002 to 2010, accounting for approximately
6% of market share, with a small (~4%) reduction in 2011/
2012. Use of newer oral hypoglycemic products remained
below 7% in Thailand throughout the study period (2.0%
in 2002 to 4.3% in 2012 in hospitals; 2.1% in 2002 to 6.9%
in 2012 in retail settings). Sulfonylureas and metformin
dominated the oral hypoglycemic market in Brazil and
Thailand over the 10-year period, although there was a rela-
tive shift in use from sulfonylureas to metformin in both
countries. Between 2002 and 2012, metformin market share
Figure 1 Market share of types of insulin by country (2002 – 2012).
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increased from 34.6% to 57.5% in Brazil, 41.8% to 56.6% in
Thai hospitals, and 35.1% to 40.8% in Thai retail settings.
Discussion
This longitudinal study showed important differences in
uptake trends of newer pharmaceutical products for
treating diabetes, a prevalent chronic condition, in three
pharmerging middle-income countries: Brazil, China,
and Thailand. Our findings suggest that health and
pharmaceutical policies of individual countries can have
substantial impact on the market share of medications
by volume of use and how quickly new agents are
adopted in healthcare systems.
China was the fastest adopter of both newer insulin and
oral hypoglycemic products. Since the early 1980s and
throughout the study period, Chinese hospitals have derived
a large proportion (more than 50%) of their operating bud-
gets from drug sales [13,14]. As such, there were strong fi-
nancial incentives to prescribe newer, more expensive
pharmaceutical products [9,13-15]. In 2009, the Chinese
government implemented a major national healthcare re-
form in response to challenges such as increased demands
for health care, inadequate health insurance, inefficient use
of healthcare resources, and poor quality of care [16,17].
Under the reform, policies were developed and imple-
mented to improve health insurance coverage, care delivery,
pharmaceutical supply and access (including through a
national essential medicines list for primary care settings
which forms the basis for insurance coverage of medicines),
and hospital management. One major goal of China’s health-
care reform is to reduce reliance on pharmaceutical sales as
revenue sources for hospitals [18]. There are as yet no data
on whether this goal has been realized; our data suggest that
sales of more expensive therapeutic alternatives for diabetes
treatment remain high. China’s higher use of newer alpha-
glucosidase inhibitors and non-sulfonylurea secretagogues
compared with Brazil or Thailand is in line with its clinical
guidelines, which recommend these agents for patients not
tolerating or responding to metformin [19]. However, it is
unclear to what extent these agents are prescribed as first-
line versus second-line therapy for diabetes.
In contrast, Thailand had the lowest use of both newer in-
sulin and oral hypoglycemic products. With the implementa-
tion of the Universal Coverage Scheme in 2001 that merged
the pre-existing Voluntary Health Card (rural population
coverage) and Medical Welfare schemes (poor and indigent
coverage), Thailand was among the first middle-income
countries to establish such schemes for its entire population
[20]. Thailand is also one of the first middle-income
countries to adopt a formal process of Health Technol-
ogy Assessment (HTA) for its coverage decisions; an
HTA unit was established in 2002 and the Health Inter-
vention and Technology Assessment Program in 2006
by the Ministry of Public Health [21]. Although Thailand
Figure 2 Market shares of oral hypoglycemic agents by country (2002 to 2012).
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has had a national essential medicines list since 1981, cost-
effectiveness, in addition to clinical efficacy and safety, was
introduced as a criterion for selecting drugs for the 2004 list
[21,22]. Our findings are consistent with a recent study that
indicates that human insulin products, metformin and sulfo-
nylureas, which are on the national essential medicines list
and covered by the Universal Coverage Scheme, dominate
the Thailand market [4]. Newer insulin and oral
hypoglycaemic products have only been covered by the Civil
Servants Medical Benefits Scheme (which insures about 9%
of the population) [23] or self-funded by patients.
The uptake of newer insulin and oral hypoglycemic
products was higher in Brazil than in Thailand. Import-
antly, Brazil was the earliest adopter of insulin analogues
and has the most use of these products overall. This
finding may reflect the fact that IMS Health data in
Brazil represent largely pharmaceutical sales from the
private sector where newer products may preferentially
Table 2 Market shares* of types of oral hypoglycemic agents by country (2002 to 2012)
2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Brazil retail
Alpha-glucosidase inhibitors 2.18 2.12 2.06 1.90 2.03 1.89 1.55 1.45 1.21 0.81 0.62
Biguanides 34.56 37.50 40.94 43.61 45.70 48.61 49.55 49.56 51.39 54.21 57.53
DPP4 inhibitors 0 0 0 0 0 0.77 2.25 2.70 2.48 2.43 2.77
Fixed dose combinations** 1.51 4.35 6.87 8.29 9.04 8.50 9.26 10.07 9.50 8.32 7.60
Non-sulfonylurea secretagogues 3.55 3.58 3.28 2.94 2.76 2.19 1.55 1.25 0.98 0.58 0.33
Thiazolidinediones 0.73 0.86 0.93 1.14 1.55 1.34 0.99 0.93 0.76 0.47 0.46
Sulfonylureas 57.48 51.60 45.93 42.12 38.92 36.70 34.85 34.04 33.68 33.19 30.69
China hospital
Alpha-glucosidase inhibitors 10.50 13.48 16.65 18.41 19.76 21.06 21.95 23.16 25.48 26.94 27.35
Biguanides 45.41 43.48 39.27 38.03 37.34 36.57 35.68 34.31 32.93 33.22 34.64
DPP4 inhibitors 0 0 0 0 0 0 0 0 0.01 0.06 0.15
Fixed dose combinations** 0 0 0 0 0 0.01 0.03 0.15 0.21 0.13 0.15
Non-sulfonylurea secretagogues 2.26 3.85 5.58 6.98 8.31 10.33 12.05 13.72 14.72 15.16 14.13
Thiazolidinediones 0.37 0.66 0.93 1.26 2.35 2.99 3.31 3.79 3.82 3.30 2.79
Sulfonylureas 41.45 38.54 37.56 35.32 32.24 29.04 26.98 24.88 22.83 21.19 20.80
Thailand hospital
Alpha-glucosidase inhibitors 1.37 1.12 1.01 1.02 1.17 1.27 1.29 1.34 1.29 1.16 1.09
Biguanides 41.79 45.92 48.30 49.27 50.45 52.09 54.78 55.11 55.26 55.00 56.63
DPP4inhibitors 0 0 0 0 0 0 0.08 0.23 0.41 0.62 0.71
Fixed dose combinations** 0 0 0.01 0.05 0.08 0.12 0.20 0.31 0.40 0.49 0.68
Non-sulfonylurea secretagogues 0.15 0.15 0.14 0.14 0.16 0.17 0.16 0.16 0.15 0.14 0.15
Thiazolidinediones 0.43 0.54 0.71 0.81 1.18 1.28 1.38 1.61 1.90 2.15 2.33
Sulfonylureas 56.26 52.27 49.83 48.71 46.96 45.06 42.11 41.25 40.58 40.45 38.41
Thailand retail
Alpha-glucosidase inhibitors 1.83 1.58 1.30 1.11 1.98 1.92 1.69 1.73 2.28 1.86 2.75
Biguanides 35.12 32.10 37.81 42.00 42.82 43.16 39.94 43.41 39.71 41.17 40.81
DPP4 inhibitors 0 0 0 0 0 0 0 0 0.16 0.62 1.31
Fixed dose combinations** 0 0 0 0 0 0 0 0.09 0.06 0.05 0.27
Non-sulfonylurea secretagogues 0 0 0.19 0.22 0.38 0.41 0.47 0.50 0.50 0.43 0.50
Thiazolidinediones 0.23 0.50 0.54 0.62 0.66 0.58 0.54 1.43 1.75 1.74 2.37
Sulfonylureas 62.82 65.82 60.16 56.06 54.16 53.93 57.35 52.83 55.54 54.12 52.00
*Market share is the percentage of the total market volume based on volume sold in standard units per 1000 population. IMS Health defines a standard unit as
the smallest common dose of a product form: one tablet or capsule for oral formulations.
**Fixed dose combinations include the following: cinnamomum loureirii & glipizide & metformin; glibenclamide & metformin; gliclazide & metformin; glimepiride
& metformin; glimepiride & rosiglitazone; glipizide & metformin; metformin & nateglinide; metformin & pioglitazone; metformin & rosiglitazone; metformin
& saxagliptin; metformin & sitagliptin; metformin & vildagliptin.
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be dispensed. Among the three countries included in
this study, Brazil was the first to make substantial pro-
gress toward increasing financial protection for health-
care expenditures for its population. Since 1989, all
citizens in Brazil have been entitled to free health care at
primary, secondary, and tertiary levels through a na-
tional health system that is funded by taxes and social
contributions, such as social security payments [24].
Interest in HTA in Brazil began in the mid-1980s. In
2003, several policies were developed by the federal gov-
ernment to encourage the use of HTA for making clin-
ical, management, and policy decisions [25]. In 2004,
Brazil introduced the Popular Pharmacy Program [8] to im-
prove access to essential medicines in the public sector. In
2006, the program was expanded to the private sector and
in 2011, selected medicines for diabetes and hypertension
became available free of charge at retail pharmacies partici-
pating in the program. The Popular Pharmacy Program
fully subsidizes human insulin but not insulin analogues; its
2011 expansion may account for the observed shift in use
from insulin analogues to human insulin in 2011 [8].
Use of new delivery devices (pens/cartridges) increased
over time in all countries, dominating the market by the
end of the study period in both China and Thailand.
While these devices offer convenience and are preferred
by patients [10], over half of these were insulin analogues.
We found that insulin analogues accounted for over a
quarter of the market share in Brazil, China, and Thailand.
These trends still trail high-income countries, where insu-
lin analogues accounted for about two-thirds of the mar-
ket share in 2009 [26]. In the context of limited resources,
choice of insulin analogue pens/cartridges over human in-
sulin pens/cartridges is questionable given the marginal
benefits of insulin analogues for type 2 diabetes and their
higher prices (3–13 folds higher) [26]. Overall, similar to
other published research [26], we found that human insu-
lin dominated the markets in the three countries, although
the proportion of analogue insulin use is approaching that
of human insulin use in China.
Overall, metformin and sulfonylureas dominated the oral
hypoglycemic market in all three countries, which is consist-
ent with global clinical guidelines for diabetes treatment [2]
and with national guidelines in the three study countries
[19,27,28].
There are notable potential limitations of this study. Our
interpretation of the data in China assumes that newer,
more expensive products represent higher profits, which
may not be correct for all hospitals. The IMS Health data
for Brazil only included pharmaceutical sales in the private
sector; thus, our analysis does not present a full picture of
medication use in this country. We did not have drug price
data or patient-level clinical data to evaluate the economic
and clinical impacts of the changing trends in insulin and
oral hypoglycemic use. Because our analysis was based on
pharmaceutical sales, we could not assess the appropriate-
ness of medication use. Lastly, while sampling changes in
Brazil and China by IMS Health affected the overall volumes
sold for all ATC classes, we calculated market share for a
product in relation to therapeutic alternatives on the market.
Unless changes in the IMS Health sampling frame differen-
tially affected inclusion of individual products, our market
share analyses are robust to sampling changes.
The observed differences in uptake of new therapeutic
agents are likely due to complex interactions among mul-
tiple actors and factors in country health systems, including
government policies to increase medicines access while con-
taining pharmaceutical expenditures, industry strategies to
increase access to and market shares of new products [29],
clinician prescribing behavior and patient preferences, and
patient and system ability and willingness to pay. It remains
to be seen how, among other factors, China’s ongoing na-
tional healthcare reform, Brazil’s strategies to increase use of
chronic disease medicines, and Thailand’s approach to
evaluating novel medicines will influence future patterns of
use of diabetes treatments. As pharmaceutical markets and
health system structures continue to evolve, it is crucial to
adapt pharmaceutical policies to generate most health value
for the resources spent [30].
Conclusions
This study compared the uptake of new insulin products and
new oral hypoglycemic medications between three middle-
income pharmerging countries between 2002 and 2012. Up-
take patterns differed markedly in the three countries. China
experienced the highest use of insulin cartridges and pens;
Brazil was the earliest adopter of insulin analogues, but use
of these products subsequently decreased by almost half; use
of newer oral hypoglycemic agents remained low in Brazil
and Thailand, but market share of these agents exceeded
44% in China by 2012. Observed differences are likely due to
different medicines policy approaches.
Future research should evaluate whether medication pre-
scribing is consistent with national clinical practice guide-
lines, essential medicines lists, and insurance reimbursement
lists; quantify the individual and system-wide economic im-
pacts of changes in utilization; and assess population health
outcomes associated with different patterns of use over
time.
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